下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEDocetaxelCat.No.:HY-B0011CASNo.:114977-28-5Synonyms:RP-56976分?式:C??H??NO??分?量:807.88作?靶點(diǎn):Microtubule/Tubulin;Apoptosis;EndogenousMetabolite作?通路:CellCycle/DNADamage;Cytoskeleton;Apoptosis;MetabolicEnzyme/Protease儲存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom
light)溶解性數(shù)據(jù)體外實(shí)驗(yàn)Ethanol:50mg/mL(61.89mM;Needultrasonic)DMSO:≥35mg/mL(43.32mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.2378mL6.1890mL12.3781mL5mM0.2476mL1.2378mL2.4756mL10mM0.1238mL0.6189mL1.2378mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;?旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限:-80°C,6months;-20°C,1month(protectfromlight)。-80°C儲存時,請?jiān)?個?內(nèi)使?,-20°C儲存時,請?jiān)?個?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶)1/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(2.57mM);Clearsolution2.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(2.57mM);Clearsolution3.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(2.57mM);Clearsolution4.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(2.57mM);Clearsolution5.請依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(2.57mM);Clearsolution6.請依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(2.57mM);Clearsolution7.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(2.57mM);Clearsolution8.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(2.57mM);Clearsolution9.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(2.57mM);Clearsolution請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(2.57mM);Clearsolution請依序添加每種溶劑:10%EtOH>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥5mg/mL(6.19mM);Clearsolution請依序添加每種溶劑:10%EtOH>>90%cornoilSolubility:≥5mg/mL(6.19mM);ClearsolutionBIOLOGICALACTIVITY?物活性Docetaxel(RP-56976)?種微管解聚(microtubuledepolymerization)抑制劑,其IC50值為0.2μM。Docetaxel紫杉醇的半合成類似物,能減弱bcl-2和bcl-xL因表達(dá)的響。Docetaxel阻滯G2/M細(xì)胞周期,導(dǎo)致細(xì)胞凋亡(apoptosis)。Docetaxel具有抗腫瘤活性。IC50&TargetHumanEndogenousMetabolite體外研究Docetaxel(RP-56976)andGlufosfamide(GLU)singleandcombinedtreatmentsaffectthecellsviabilityinadose-dependentmanner.TheIC50ofGLUare70±4μMand86.8±8μMinPC-3andLNCaPcells;respectively.While,theIC50ofDocetaxelaloneisfoundtobe3.08±0.4nMand1.46±0.2nMinPC-3andLNCaPcells;respectively.Theco-treatmentofGLUwithDocetaxelisfoundtosynergizethecytotoxicityandtheIC50valuesaredecreasedtobe2.7±0.1nMand0.75±0.3nMinPC-3andLNCaPcells;respectively[1].IC50ofNCI-H460toDocetaxelat24his116nMandat72his30nM.AccordingtodatareportedinDTPDataSearch,themeanIC50ofNCI-60cellpaneltoDocetaxelis14-34nM[2].體內(nèi)研究Infemalemice,theDocetaxel(RP-56976)-inducedintestinalapoptosisinthe14-hoursafterlighton(HALO)groupissignificantlygreaterthanthatinthe2-HALOgroup.Baxexpressionissignificantlyelevatedby2/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEDocetaxelinthe2-HALOgroup,butnotinthe14-HALOgroup.Ontheotherhand,cleavedCaspase-3expressionissignificantlyelevatedbyDocetaxelinthe14-HALOgroup,butnotinthe2-HALOgroup.TheexpressionsofWee1andphosphorylatedCKD1aresignificantlyelevatedafterdosingofDocetaxelat14HALO,butnotat2HALO.Inaddition,Docetaxelsignificantlyreducessurvivinexpressioninthe14-HALOgroupbutnotinthe2-HALOgroup.ThesurvivinexpressionlevelintheDocetaxel-treated14-HALOgroupissignificantlysmallerthanthatinthedrug-treated2-HALOgroup[3].Piperine(PIP)isadministratedviaintravenousbolusat3.5mg/kgandviaoraladministrationat35mg/kgand3.5mg/kg,whileDocetaxel(DOX)isintravenouslyadministratedat7mg/kgtoSprague-Daleyrats.Theco-administrationsofPIPat35mg/kgviaoraladministrationandDocetaxelat7mg/kgviaintravenousbolusadministrationinSprague-Dawleyrats.ThecombinationuseofPIPandDocetaxelresultsinasynergicincreaseofboththeirinvivoexposure[4].PROTOCOLCellAssay[1]Single-drugconcentration-responsecurvesareassessed.Seedingisdoneatadensityof2,000cells/wellforPC-3andLNCaP,in96-wellplates.Cellsaretreatedwitheachsingledrugandtheircombinationfor72hatdifferentdrugconcentrations.Docetaxelisusedatconcentrationsof0.1-1,000nM.GLUisusedatconcentrationsof0.1-300μm.CytotoxicityisassessedattheendofdrugexposureusingSRBassay.Following72hexposurethecellsarefixedwith10%trichloroaceticacid(150μL)for1hat4°C.Then,cellsarestainedfor10minatroomtemperaturewith0.4%SRBdissolvedin1%aceticacid.Theplatesarethenairdriedfor24handthedyeismadesolublewith150μLTris(10mM,PH7.4)for5minonashakerat1,600rpm.Absorbanceisthenmeasuredat545nMusingmicroplatereader.Resultsareexpressedastherelativepercentageofabsorbancecomparedtocontrol[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalMice[3]Administration[3][4]Five-week-oldmaleBalb/cmiceareused.Docetaxel(0,10,20,30,40,60,and80mg/kgperweek)isgivenonceaweekfor3weeksformice.Becausemorethan30mg/kgperweekofDocetaxelcausesbodyweightlossinmice,20mg/kgperweekofDocetaxelisjudgedtobethemaximumnontoxicdose.Docetaxel(20mg/kgperweek)isgiventomiceonceaweekfor3weeksatoneofthefollowingdifferentpoints(2,10,14,or22HALO).Seventy-twohoursafterthefinaldosingoftheagent,theintestinalmucosaofthesmallintestine(proximal8cm)isremoved,fixedin20NMildformsolution(containing8%formaldehydeinabufferedsolution),andembeddedinparaffinblocks,andsectionsof5μmareputonglassslides.Apoptosisisdetectedusingtheterminaldeoxynucleotidyltransferase-mediateddUTPnick-endlabeling(TUNEL)method,usingtheApopTagPeroxidaseInSituApoptosisDetectionKit.Rats[4]MaleSprague-Dawleyratswithbodyweightbetween230-250gandagebetween6-7weeksareused.About25SDratsaredividedintofivegroupsreceivingDocetaxel(7mg/kg,i.v.),PIP(35mg/kg,p.o.)andtheircombinedadministration(DOX+PIP)aswellasPIP(3.5mg/kg,p.o.)andPIP(3.5mg/kg,i.v.).Adaybeforethedrugadministrations,theratsareanesthetized.Rightjugularveiniscannulatedwithapolyethylenetubing(0.5mmID,1mm)forbloodcollection.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.3/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?SignalTransductTargetTher.2022Sep12;7(1):317.?ACSNano.2021Apr27;15(4):7179-7194.?EurUrol.2020Nov2;S0302-2838(20)30778-8.?Biomaterials.2September2022,121783.?ActaPharmSinB.2020June29.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].AttiaRT,etal.Thechemomodulatoryeffectsofgl
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年華東師大版必修3地理下冊月考試卷含答案
- 2025年外研版八年級物理下冊階段測試試卷含答案
- 2025年人教版選擇性必修3化學(xué)下冊階段測試試卷含答案
- 現(xiàn)代家庭的安全與環(huán)保家用紡織品趨勢報告
- 社區(qū)醫(yī)院修繕項(xiàng)目用工協(xié)議
- 2025至2030年中國瓷紙杯數(shù)據(jù)監(jiān)測研究報告
- 2025至2030年中國渣漿數(shù)據(jù)監(jiān)測研究報告
- 2025年滬科新版七年級科學(xué)下冊月考試卷含答案
- 2025至2030年中國技師工裝數(shù)據(jù)監(jiān)測研究報告
- 2025年冀教版七年級數(shù)學(xué)下冊階段測試試卷含答案
- 巖土工程勘察課件0巖土工程勘察
- 《腎上腺腫瘤》課件
- 2024-2030年中國典當(dāng)行業(yè)發(fā)展前景預(yù)測及融資策略分析報告
- 《乘用車越野性能主觀評價方法》
- 幼師個人成長發(fā)展規(guī)劃
- 2024-2025學(xué)年北師大版高二上學(xué)期期末英語試題及解答參考
- 動物醫(yī)學(xué)類專業(yè)生涯發(fā)展展示
- 批發(fā)面包采購合同范本
- 乘風(fēng)化麟 蛇我其誰 2025XX集團(tuán)年終總結(jié)暨頒獎盛典
- 2024年大數(shù)據(jù)分析公司與中國政府合作協(xié)議
- 一年級數(shù)學(xué)(上)計算題專項(xiàng)練習(xí)匯編
評論
0/150
提交評論